Drug intelligence / Profile preview

ASP1707 + methotrexate

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASP1707 + methotrexate is a combination therapy investigated for treatment of moderate to severe active rheumatoid arthritis (RA) in postmenopausal female patients. ASP1707 (also known as opigolix) is an oral gonadotropin-releasing hormone (GnRH) antagonist, which rapidly and potently suppresses circulating luteinizing hormone. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits folate pathway enzymes crucial for cell nucleotide synthesis, leading to suppression of inflammation and immune modulation. Studies found that the combination was safe and well tolerated but did not show clinical efficacy in RA[1][5][3][7].

Other names: opigolix + methotrexate

Targets

DHFR (Dihydrofolate reductase)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on ASP1707 + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP1707 + methotrexate.

Explore the full profile